Thrombosis

AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

AHA 2017 BRUISE CONTROL 2 was a blinded randomized trial that compared periprocedural continuation or interruption of DOAC therapy and found similarly low rates of CVA/TIA and hematoma.

Background

Oral anticoagulant therapy is comm...

Stepwise higher concentrations of nonfasting triglycerides were associated with a stepwise higher risk of heart failure, which was not the case for LDL-c.

In a large retrospective cohort study, the risk of dementia was higher without oral anticoagulant treatment in patients with AF, compared with AF patients receiving oral anticoagulation.

Background

Atrial fibrillation (AF) is associated...

An analysis of the REVEAL AF study, demonstrated a substantial incidence of previously undiagnosed AF when insertable cardiac monitors were used for 18 to 30 months in patients at high risk for AF and stroke.

A randomized, cross-over study showed a stronger antiplatelet effect and a faster and more potent antithrombotic effect with ticagrelor than with clopidogrel in T2DM patients with stable CVD.

Background

Type 2 diabetes (T2DM) patients have a high risk of CV morbidity and mortality, which i...

In the AFFIRM study, SBP variability was inversely associated with the quality of anticoagulation control in AF patients, and increasing SBP variability was associated with a higher risk of major adverse clinical outcomes.

In the IMPROVE-IT study, the addition of ezetimibe to simvastatin in stabilized post-ACS patients reduced the frequency of ischemic stroke, particularly in patients with a history of prior stroke.

ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..

RE-DUAL PCI: Dual Antithrombotic Therapy with Dabigatran after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation

Presented at the ESC congr...

ESC 2017 Positive results for COMPASS trial, in which CV death, stroke or myocardial infarction risk are improved with NOAC rivaroxaban plus aspirin, as well as for COMPASS-PAD trial.

Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)

Presented at the ESC congress 2017 by: John William Eikelboom (Hamilton, ON...

The discontinuation of statin therapy 3 to 6 months after an index ischemic stroke event, was associated with a higher risk of recurrent stroke within 1 year after statin discontinuation.

Background

Guidelines rec...

A large meta-analysis of nine studies confirmed association of PCSK9 loss-of-function variants with lower LDL-C levels and lower coronary heart disease risk, but not with stroke risk.

Complete data set from 503 patients show that idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of dabigatran etexilate in emergency settings.

Final results from RE-VERSE AD were presented as a late-breaker at the ISTH 2017 Congress in Berlin, Germany. The data show that idarucizumab was able to immediately and completely...

In a large population-based cohort study, BMI was associated with risk of hypertension, CHD, T2DM, elevated SBP and DBP based on causal mendelian randomization estimates, but not with stroke or pulse rate.

Background

Cor...

After rigorous adjustment for confounding factors, a propensity scoring analysis of a large Korean cohort revealed increased risk for stroke and myocardial infarction after herpes zoster infection.

Background

The association between herpes zoster and stroke and myoca...

In elderly patients on aspirin-based antiplatelet therapy without routine proton-pump inhibitor use, the long-term risk of disabling or fatal GI bleeding is 10 time higher, compared with younger age groups.